Kornimate/medical-research-clean huggingface dataset:
combination chemotherapy in treating older patients with solid tumour,

Conditions: Solid Tumor Regardless of Localization and Stage

Summary: rationale: drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. giving more than one drug (combination chemotherapy) may kill more tumor cells. purpose: this clinical trial is studying how well combination chemotherapy works in treating older patients with solid tumour.

objectives: primary * to determine a prognostic scale of the feasibility of chemotherapy (at least two-thirds of the dose intensity usually administered) in patients aged 75 years or older with solid tumour. secondary * to evaluate the efficacy, in terms of clinical and/or biological response, of treatments administered. * to evaluate the incidence of severe (grade 3-4) toxicity. outline: this is a multicenter study. patients receive one of the following regimens according to cancer diagnosis and principal investigator preference. all regimens last 3 months.

Eligibility criteria:
disease characteristics: * histologically confirmed solid tumour regardless of localization or stage patient characteristics: * \> or = 75 years * patient planned to receive \> or = 2/3 of standard dose of the first cycle prior concurrent therapy: chemonaive patient.
noninvasive markers of functional nausea in children

Conditions: Nausea

Summary: the researchers propose to study how functional nausea in adolescents may be characterized noninvasively by the use of multichannel electrogastrogram (egg) and magnetogastrogram (mgg) recordings.

5/23/25. study record updated to reflect early phase i trial as opposed to "n/a". the main aims were to develop a mathematical model of fn, correlate functional differences in slow waves in fn patients using modeling and experimental approaches, and to characterize biophysical, clinical, and psychosocial phenotypes of fn using newly developed diagnostic devices of egg/mgg. functional nausea (fn) is a gi disorder that affects millions of americans, particularly adolescents, but diagnoses remain largely exclusionary relying on symptomology with an otherwise normal diagnostic workup. successful completion of the project could contribute to understanding the altered physiology of functional nausea (fn), to stratification of fn patients according to physiological and/or psychological phenotypes, to improve diagnosis and provide objective measures of nausea and to inform and guide treatment options. the analysis of slow wave activity represents the first physiologically-quantifiable noninvasive assessment method for pathological processes associated with functional nausea in adolescents.

Eligibility criteria:
inclusion criteria: * children ages 8-17 with functional nausea * normal control participants ages 8-17 who have no known gastrointestinal complications exclusion criteria: * those with claustrophobia who cannot lie still under the squid for the length of time required. * normal participants with known intestinal complications * patients with cyclic vomiting syndrome, gastroparesis, malignancy, primary eating disorders, pregnancy, or hyperglycemia * morbid obesity (these patients are presumably unable to lie under the current generation of squid devices). * patients with a history of cardiac arrhythmias or taking anticoagulants will be excluded
home use of automatic external defibrillators to treat sudden cardiac arrest

Conditions: Cardiovascular Diseases; Myocardial Infarction; Heart Diseases; Death, Sudden, Cardiac

Summary: to compare home use of an automatic external defibrillator (aed) to the use of local emergency medical system in treating survivors of sudden cardiac arrest.

background: sudden cardiac arrest (sca) occurs every two minutes throughout the united states, with more than 70 percent occuring at home. because survival falls 10 percent per minute over the first ten minutes, it is imperative to defibrillate as soon as possible. public efforts cannot provide defibrillation fast enough in most cases. physicians believe the initial shock is best done using readily available aeds by family members who are only seconds from their loved one. design narrative: this study tests the central hypothesis that providing an aed for home use will improve survival beyond that achieved from the typical response to sudden cardiac arrest. an estimated 7,000 people who have had an anterior myocardial infarction will be randomly assigned to one of two groups: 1) a standard response to sudden cardiac arrest, entailing calling an emergency medical service (ems) system and performing cpr, or 2) the addition of a home aed to the standard response. the standard response will be augmented and standardized by the provision of a video on how to respond to sudden cardiac arrest and how to perform cpr. the goal for the standard response will be immediate notification of ems and prompt cpr. the goal for the aed group will be to shock the cardiac arrest victim up to three times immediately, if indicated by the aed, and call ems and perform cpr as soon as possible and preferably within two minutes of collapse. participants will be enrolled for more than two years and followed for an additional two years. the study will be performed at 200 cardiology clinics.

Eligibility criteria:
inclusion criteria: * history of anterior myocardial infarction * live-in spouse or companion willing to administer cpr or aed therapy plus cpr exclusion criteria: * existing implantable cardiac defibrillator or aed * current candidate for an implantable cardiac defibrillator * current "do not resuscitate" orders

Keywords: cpr, aed
effect of low-level laser therapy on type ii controlled diabetic patients after dental implant insertion

Conditions: T2DM (Type 2 Diabetes Mellitus); Low-level Laser Therapy; Bone Density Increased

Summary: this study aimed therefore to evaluate bone density (bd) and opg levels in the peri-implant crevicular fluid (picf) in lased controlled type ii diabetes mellitus (t2dm) patients versus non-lased t2dm patients. 40 t2dm patients were included in this study. implants were randomly inserted in 20 non-lased t2dm patients (control) and 20 lased t2dm patients (intervention). bd and opg levels in the picf were assessed in both groups at the follow up points.

background and objectives: use of low-level laser therapy (lllt) with dental implants has been suggested to improve bone quality during osseointegration. however, there is a lack of evidence about its influence on dental implants in diabetic patients. osteoprotegrin (opg) levels was reported as a biomarker for bone turnover to distinguish implant prognosis. this study aimed therefore to evaluate bone density (bd) and opg levels in the peri-implant crevicular fluid (picf) in lased controlled type ii diabetes mellitus (t2dm) patients versus non-lased t2dm patients. methods: 40 t2dm patients were included in this study. implants were randomly inserted in 20 non-lased t2dm patients (control) and 20 lased t2dm patients (intervention). bd and opg levels in the picf were assessed in both groups at the follow up points.

Eligibility criteria:
inclusion criteria: * none of the participants had other major illnesses or severe diabetic complications. * a detailed medical history of each subject was obtained according to the detailed questionnaire of the modified cornell medical index \[22\]. * diabetic control was measured by glycosylated hemoglobin a1c (hba1c) of blood samples, patients had relatively stable glycemic control, as demonstrated by a difference not exceeding 1% in at least two hba1c assays over the previous 6 months. * participants with partial edentulous posterior mandibular region with bone density ranging between d2 and d3, also having adjacent tooth with healthy periodontium were selected. exclusion criteria: * any uncontrolled systemic diseases that prevent surgery for dental implant placement; (b) need for guided bone regeneration or sinus lift for implant placement, and (c) history of radiation therapy in head and neck. * pregnant women, smokers and patients with para-functional habits, psychological problems or in-cooperated patients were also excluded.

Keywords: t2dm (type 2 diabetes mellitus) dental implant insertion osteoprotegrin (opg) bone density low-level laser therapy lllt
effects of physiotherapy via telerehabilitation in patients with covid-19

Conditions: COVID-19; Long COVID-19; Cardiopulmonary Function; Physical Function

Summary: this study aims to evaluate the effects of physiotherapy via video calls on cardiopulmonary functions, physical function, cognitive function, activity daily livings, and quality of life in patients with covid-19.

a 2-armed, parallel-group, randomized controlled trial was conducted at chulabhorn hospital, thailand on a convenience sample of patients who tested positive for covid-19 using rt-pcr.

Eligibility criteria:
inclusion criteria: * age between 20-60 years old * positive in covid-19 testing * good communication and understanding * independent mobility exclusion criteria: * cannot complete the study protocol
treatment for bile duct cancer in the liver

Conditions: Cholangio Carcinoma

Summary: the current standard treatment of inoperable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) is chemotherapy, which is of limited efficacy. the use of selective internal radiotherapy treatment (sirt-y90) is proven efficacious in patients with intra-heptic tumor. previous experience with sirt is safe in patients with intrahepatic cholangiocarcinoma. this study aims to study the benefits of sequential administration of sirt followed by standard chemotherapy for treatment of inoperable intrahepatic cholangiocarcinoma.


Eligibility criteria:
inclusion criteria: * age\>18 years * histological or cytological diagnosis of cholangiocarcinoma * disease not amenable to surgery * predominant disease load in the liver (in case of extra-hepatic involvement, only patients with lymph nodes metastases are allowed) * naïve to locoregional or systemic treatment (but patients who develop recurrent disease after surgery are suitable) * ecog ps 0-1 * at least one measurable disease lesion according to recist v 1.1 * life expectancy of 12 weeks or longer * adequate hematological, renal and hepatic function * platelet ≥100 x 109 * anc ≥ 1.5 x 109 * bilirubin ≤ 30µmol/l * albumin ≥ 30g/l * alt ≤ 3 uln * inr ≤ 1.5 * serum creatinine ≤ 1.5 x uln exclusion criteria: * prior malignancy except cervical carcinoma-in-situ or treated basal cell carcinoma. any cancers treated curatively \> 5 years prior to study entry are permitted. * patients with extra-hepatic disease other than regional lymph node metastases. * evidence of ascites or cirrhosis, as determined by clinical or radiologic assessment * biliary obstruction with no possibility of drainage * non-malignant disease that would render the patient unsuitable for treatment according to the protocol * prior treatment of chemotherapy for the cholangiocarcinoma * prior radiation therapy to the upper abdomen * complete thrombosis of the main portal vein * tumor volume \> 50% of the normal liver volume * allergy to non-ionic contrast agents
open retropubic versus laparoscopic colposuspension (burch operation) techniques for female stress or mixed urinary incontinence; a ten-year experience in a tertiary center

Conditions: Stress Urinary Incontinence

Summary: to evaluate postoperative course, efficacy, and complication rates of open burch colposuspension and laparoscopic burch colposuspension techniques in stress or mixed urinary incontinence at a single training and research hospital over the last 10 years in istanbul, turkey.

a retrospective cohort study was conducted in all burch colposuspension cases performed between january 2001 and may 2022 at kanuni sultan süleyman training and research center. all patients' data were reviewed from the electronic medical records and analyzed who underwent burch colposuspension surgery either with an open or laparoscopic approach. the primary outcome was surgical success, whereas secondary outcomes were perioperative and postoperative data including surgical type (open or laparoscopic), operating time, duration of hospital stay, estimated blood loss, complications during surgery, and additional interventional procedure types.

Eligibility criteria:
inclusion criteria: * patients having sui or mixed urinary incontinence whom conservative therapy (kegel's pelvic floor exercises, bladder training, electrical stimulation, or medication) failed * sui had been proven by urodynamic assessments. * patients who had urethral hypermobility supported by a q-type test with a cotton swab angle greater than 300 * patients having a residual urinary volume of less than 100 ml were included. exclusion criteria: * history of anti-incontinence surgery * pelvic inflammatory diseases * urinary retention * sui with intrinsic sphincter deficiency * neurogenic bladder * suspected malignancy * urge incontinence * chronic cystitis * urinary tract infection * prescription of anticoagulant or antipsychotic treatment * coagulation disorders * physically and medically unsuitable for colposuspension surgery * pregnancy and loss to follow-up.

Keywords: burch colposuspension laparoscopy outcome retropubic stress urinary incontinence
intelligent activity-based client-centred training

Conditions: Central Nervous System Diseases; Aged

Summary: the purpose of this study is to determine whether additional therapy with i-act system is effective in the training of functional skills in persons with central neurological diseases (e.g. multiple sclerosis, stroke, spinal cord injury, etc.).


Eligibility criteria:
inclusion criteria: * medical diagnosis of central nervous system disease (e.g. multiple sclerosis, stroke, spinal cord, etc.) * be able to understand and respond to questions in dutch * actively involved in a rehabilitation programme in the participating rehabilitation centres * have a dysfunction in upper and/or lower limb and/or core stability * specifically for multiple sclerosis: min. of one month without corticosteroids * specifically for stroke and spinal cord: min. 3 months post injury exclusion criteria: * severe spasticity which prevent performing basic functional exercises * severe cognitive and communicative impairment which prevent the person to understand and respond to dutch instructions * severe visual impairment, e.g. blindness, cataract, etc. * pregnancy * persons who use an electrical wheelchair, who can not transfer safely into a normal chair and perform the exercises

Keywords: activity-based client-centred rehabilitation quality of life
remote study collecting blood glucose values and activity data in patients with type 2 diabetes on different treatments

Conditions: Diabetes Mellitus, Type 2

Summary: earlier protocol id was nn1250-4630, protocol id is changed to nn1535-7774. the purpose of this study is to collect blood glucose values and activity data in patients with type 2 diabetes for approximately 12 weeks using electronic devices in a full virtual clinical setting. virtual clinical setting means that all data are collected by use of participants' personal smartphone and study-related apps. in other words, everything will be handled without any visits to a hospital or doctor. for collection of participants' blood glucose values participants will receive two different blood glucose monitors. one where participants cannot see the blood glucose values and one where participants can see the blood glucose values. participants must wear them consecutively for 2 and 10 weeks, respectively. further, participants will be asked to self-apply the monitors on their upper arm. for collection of participants' activity data participants will receive an activity tracker, which participants will wear on the wrist throughout the study. the study does not include any study medication and participants will continue the current antidiabetic treatment as prescribed to participants by their own physician. if any questions about the treatment and/or health condition while participating in the trial, participants should consult your own physician if participants are in doubt about what the blood glucose values mean or whether participants should react to the blood glucose values, participants need to contact the research staff or their general practitioner.


Eligibility criteria:
inclusion criteria: * willingness to consent via the e-consent process before any study-related activities takes place (study-related activities are any procedure related to recording of data according to the protocol) * male or female, age above or equal to 18 years at the time of signing informed consent * diagnosed t2dm for more than 3 months prior to signing the informed consent * on one of the following treatments for t2dm: 1. metformin ± other oads 2. basal insulin ± oads 3. glp-1 ± basal insulin (loose and fixed combination) ± oads * willingness to, and capable of applying and using the study devices * willingness to follow study procedures * fluent in danish both oral, reading and in writing * in possession of a compatible smartphone throughout the study, meaning that the smartphone fulfils the criteria to the operating system for using the devices needed for the study exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * participation in any other study investigating diabetes. * patients who do not have a blood glucose meter at home
comparison of postoperative pain application of alfentanil or remifentanil in tiva

Conditions: Postoperative Pain

Summary: total intravenous anesthesia (tiva) is maintained by intermittent or continuous combined intravenous injection of a variety of short-acting intravenous anesthetics, which can provide safe and rapid induction, maintenance and termination of general anesthesia. it has a slight effect on respiration and circulation, strong controllability, short anesthetic recovery time, reduced postoperative nausea and vomiting (ponv) and quick discharge time, so it has been widely used in clinic. functional endoscopic sinus surgery is a common method for the treatment of sinusitis and other diseases. the trauma of this operation is less. the use of tiva during the operation can reduce the bleeding in the surgical field and is beneficial to the recovery of patients. the combination of propofol and remifentanil is the most common in tiva because of its fast pharmacokinetics and short half-life. however, the disadvantage of remifentanil is the lack of residual analgesic effect after termination of continuous infusion. as postoperative nasal packing can still bring postoperative pain, patients with severe discomfort caused by pain will have unexpected conditions such as surgical incision cracking and bleeding, which will affect the effect of operation and rehabilitation. afentanil is another opioid drug with short effect and strong analgesic effect. previous studies have shown that remifentanil-based tiva has slightly higher postoperative pain and early use of analgesics than tiva in discectomy. because the effect of tiva using afentanil or remifentanil on postoperative pain in functional nasal endoscopic surgery is not clear, this study intends to observe the effect of tiva on postoperative pain in patients undergoing functional nasal endoscopic surgery under general anesthesia, so as to optimize the clinical anesthetic scheme of this kind of minimally invasive surgery and provide clinical reference.

this study intends to observe the effect of tiva using afentanil or remifentanil on postoperative pain in patients undergoing functional nasal endoscopic surgery under general anesthesia. main indicators: vas score at 30 min after operation. secondary indicators: vas score of 60 min after operation. vas score of 24h after operation. number of cases of postoperative use of analgesics . number of cases of postoperative adverse reactions.

Eligibility criteria:
inclusion criteria: * age 18-65 years old * asa ⅰ-ⅲ * patients undergoing functional endoscopic sinus surgery under general anesthesia. exclusion criteria: * significant hypertension (diastolic blood pressure \> 100mmhg) or hypotension (systolic . blood pressure \< 100mmhg). * severe mental, cardiovascular, kidney or liver disease. * previous history of alcohol or drug abuse. * long-term use of painkillers before operation. * contraindications for any drugs used in the study.

Keywords: functional endoscopic sinus surgery postoperative pain afentanil or remifentanil
stress and sugar synergy

Conditions: Metabolic Syndrome; Insulin Resistance; Dyslipidemia

Summary: the main objectives of this study are to test the hypotheses that: 1) consumption of beverages sweetened with sucrose will increase risk factors for cardiovascular disease to a greater extent than a naturally-sweetened fruit juice such as orange juice, and 2) chronic psychological stress may augment the adverse metabolic effects of sugar intake. the study intervention consists of 2-week's consumption of 25% of energy as sugar provided either as a sucrose-sweetened beverage or naturally-sweetened orange juice.


Eligibility criteria:
inclusion criteria: * body mass index between 28-35 * self report of stable body weight during the past six months * high stress participants: perceived stress scores (pss) ≥ 24, and the presence of a predefined chronically stressful event as assessed by the telephone screening questions. (ids scores are not an inclusion criteria in this group, merely a rule-out for the low stress participants). * low stress participants: pss scores ≤ 8, inventory for depressive symptom (ids) scores ≤ 14, and the absence of any predefined chronically stressful events as assessed by the telephone screening questions. exclusion criteria: * glucose intolerance * evidence of liver disorder * evidence of kidney disorder * evidence of thyroid disorder * systolic blood pressure consistently over 140mmhg or diastolic blood pressure over 90mmhg * triglycerides \> 200mg/dl * ldl-c \> 130mg/dl * hemoglobin \< 8.5 g/dl * pregnant or lactating women * current, prior (within 12 months), or anticipated use of any hypolipidemic or anti-diabetic agents * use of selective serotonin reuptake inhibitors and anti-hypertensive medications * any other condition that, in the opinion of the investigators, would put subject at risk * strenuous exerciser * surgery for weight loss * diet exclusions: food allergies, special dietary restrictions, habitual ingest of \>2 alcoholic beverages/day

Keywords: sugar sucrose fruit juice orange juice metabolism immune cell aging lipids